274 related articles for article (PubMed ID: 31910895)
1. Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI.
Leijenaar JF; Groeneveld GJ; Klaassen ES; Leeuwis AE; Scheltens P; Weinstein HC; van Gerven JMA; Barkhof F; van der Flier WM; Prins ND
Alzheimers Res Ther; 2020 Jan; 12(1):10. PubMed ID: 31910895
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial.
Leijenaar JF; Groeneveld GJ; van der Flier WM; Scheltens P; Klaassen ES; Weinstein HC; Biessels GJ; Barkhof F; Prins ND
JMIR Res Protoc; 2018 Mar; 7(3):e80. PubMed ID: 29559423
[TBL] [Abstract][Full Text] [Related]
3. Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI.
Leijenaar JF; Ingala S; Sudre CH; Mutsaerts HM; Leeuwis AE; van der Flier WM; Scheltens P; Weinstein HC; Barkhof F; van Gerven J; Groeneveld GJ; Prins ND
Cereb Circ Cogn Behav; 2022; 3():100128. PubMed ID: 36324417
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine for vascular cognitive impairment.
Birks J; McGuinness B; Craig D
Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
[TBL] [Abstract][Full Text] [Related]
5. Galantamine for vascular cognitive impairment.
Birks J; Craig D
Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
[TBL] [Abstract][Full Text] [Related]
6. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Peters O; Lorenz D; Fesche A; Schmidtke K; Hüll M; Perneczky R; Rüther E; Möller HJ; Jessen F; Maier W; Kornhuber J; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Teipel S; Wellek S; Frölich L; Heuser I
J Nutr Health Aging; 2012; 16(6):544-8. PubMed ID: 22659994
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapy for Vascular Cognitive Impairment.
Farooq MU; Min J; Goshgarian C; Gorelick PB
CNS Drugs; 2017 Sep; 31(9):759-776. PubMed ID: 28786085
[TBL] [Abstract][Full Text] [Related]
8. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Small G; Erkinjuntti T; Kurz A; Lilienfeld S
CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
[TBL] [Abstract][Full Text] [Related]
9. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.
Burns A; Bernabei R; Bullock R; Cruz Jentoft AJ; Frölich L; Hock C; Raivio M; Triau E; Vandewoude M; Wimo A; Came E; Van Baelen B; Hammond GL; van Oene JC; Schwalen S
Lancet Neurol; 2009 Jan; 8(1):39-47. PubMed ID: 19042161
[TBL] [Abstract][Full Text] [Related]
11. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
12. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
13. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.
Kishi T; Ikuta T; Oya K; Matsunaga S; Matsuda Y; Iwata N
Int J Neuropsychopharmacol; 2018 Aug; 21(8):748-757. PubMed ID: 29762677
[TBL] [Abstract][Full Text] [Related]
14. Stratifying drug treatment of cognitive impairments after traumatic brain injury using neuroimaging.
Jenkins PO; De Simoni S; Bourke NJ; Fleminger J; Scott G; Towey DJ; Svensson W; Khan S; Patel MC; Greenwood R; Friedland D; Hampshire A; Cole JH; Sharp DJ
Brain; 2019 Aug; 142(8):2367-2379. PubMed ID: 31199462
[TBL] [Abstract][Full Text] [Related]
15. Comparison of vascular cognitive impairment--no dementia by multiple classification methods.
Ma J; Zhang Y; Guo Q
Int J Neurosci; 2015; 125(11):823-30. PubMed ID: 25295621
[TBL] [Abstract][Full Text] [Related]
16. Influence of Methylphenidate on Long-Term Neuropsychological and Everyday Executive Functioning After Traumatic Brain Injury in Children with Secondary Attention Problems.
LeBlond E; Smith-Paine J; Riemersma JJ; Horn PS; Wade SL; Kurowski BG
J Int Neuropsychol Soc; 2019 Aug; 25(7):740-749. PubMed ID: 31178001
[TBL] [Abstract][Full Text] [Related]
17. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
18. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
[TBL] [Abstract][Full Text] [Related]
19. 3‑N‑Butyphthalide improves learning and memory in rats with vascular cognitive impairment by activating the SIRT1/BDNF pathway.
Tian A; Li W; Zai Q; Li H; Zhang RW
Mol Med Rep; 2020 Jul; 22(1):525-533. PubMed ID: 32377741
[TBL] [Abstract][Full Text] [Related]
20. Executive dysfunction in vascular cognitive impairment in the consortium to investigate vascular impairment of cognition study.
Moorhouse P; Song X; Rockwood K; Black S; Kertesz A; Gauthier S; Feldman H;
J Neurol Sci; 2010 Jan; 288(1-2):142-6. PubMed ID: 19840883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
